In the Spotlight: ‘When you’re in a minority group, you’re never just a grad student’ – Scope

No day is the same for Carolyn Dundes, a PhD candidate in the Stem Cell Biology and Regenerative Medicine program and an LGBTQ community advocate. That's just the way Dundes likes it.

Dundes spoke with me aboutresearch, activism outside the lab and the importance of "finding your community."

Where were you before you came to Stanford?

I did my undergraduate degree at Wesleyan University. I loved it there. I did a lot of research in the lab of ProfessorLaura Grabel, PhD, studying the signals that regulate embryonic brain development.

What got you interested in that field?

Science is something I've always been super interested in, particularly the mystery of how the brain develops. I remember thinking, "How have people not figured this out yet?" Turns out it's really hard, that's why!

My first research experience was at the University of Connecticut. We were studying a really cool -- to the extent that you can say any disease is cool -- epigenetically-inherited disease called Prader-Willi Syndrome. Depending on whether the genetic error is passed down on the maternal or paternal copy of the chromosome, the observable characteristics of the disease -- known as the phenotype -- are different.

The lab was super welcoming and they patiently answered all of my endless questions. From then on, I knew I wanted to do research forever. It's a really cool transition from learning all these concepts in books and classes to actually doing an experiment and generating brand new data.

What does a day in your life look like?

One of the things I enjoy about being a grad student is that no two days look the same. I'm a member of the Loh Lab. We use human pluripotent stem cells, which have the potential to develop into any of the body's cell types, to model and better understand early stages of human development.

My research focuses on central nervous system development: I'm trying to establish which signals are instructing cells in the embryo to become all the different types of cells that make up the brain.

In the morning, I come into the lab to do cell culture. In the middle of the day, I have meetings and seminars, and in the afternoons, I do lots of different kinds of assays. That's also generally when I do my outside-of-the-lab activities. I'm on the staff at Queer Student Resources, and on Fridays, I work with the Stanford Prison Education Project.

Tell me more about your advocacy work.

The prison education project is a misnomer, since we currently work only in jails, but Stanford graduate students lead weekly seminars for individuals who are incarcerated at two local correctional centers. The students have different levels of education; some didn't finish high school, while others have advanced professional degrees. The trick is making the lesson fit all those levels. This semester, the theme was virtue and vice. Our role there was not to tell them how to be good or bad people but to discuss how we as a society decide what is virtue and what is vice.

At Queer Student Resources, I'm one of the coordinators for Trans&, a weekly event for transgender folks at Stanford to connect and spend time together. We welcome all students (undergrad, grad and postdoc) and community members who identify with any trans/non-binary/genderqueer identity, or who may be questioning their gender identity.

As a nonbinary scientist, running Trans@ has been a an important way for me to connect with other gender-minority peers at Stanford. Being an advocate is important to me because being a graduate student is already hard enough, and if you're in a disenfranchised or minority group, you can never just be a grad student. At Stanford, people are at least willing to listen to these students' needs, but there's still so much progress that needs to be made, for example when it comes to representation.

Do you have any advice for future graduate students?

First of all, it's important to find your community, whatever that means for you, and to find advocates who are willing to stick out their necks for you. That's easier said than done.

Second, I'd say find something that you love to do that has nothing to do with your work. I do dog-sitting almost every night, and that brings me great joy.

Are you watching or reading anything good lately?

I just finished listening to "Tranny" by Laura Jane Grace, the frontwoman for the pop-punk band "Against Me!" And I've been listening to the storytelling podcast, "The Moth."I like how human it is. After spending all day looking at cells under a microscope, it can be nice to be reminded of the bigger picture.

Photo by Luke Girard/Thru Luke's Lens

Read the original:
In the Spotlight: 'When you're in a minority group, you're never just a grad student' - Scope

Umbilical Cord Blood (UCB) Stem Cell Market 2019 Industry Analysis focusing on Companies Analysis-Advanced Cell Technology, Athersys, California Stem…

Umbilical Cord Blood (UCB) Stem Cell Market 2019 Global Industry Report covers the SWOT analysis of the industry along with key developments, size, share, growth and demand in the market that will be helpful for the customer. Anyone with either academic of business interest in the Umbilical Cord Blood (UCB) Stem Cell Market the report will definitely by handy

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells.

For Sample Copy of this Report athttps://www.orianresearch.com/request-sample/753860

Scope of the Report:

This report focuses on the Umbilical Cord Blood (UCB) Stem Cell in global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, types and applications.

Umbilical Cord Blood (UCB) Stem Cell Industry 2019 Market Research Report is spread across 118 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on reporthttps://www.orianresearch.com/enquiry-before-buying/753860

Report Covers Market Segment by Manufacturers:

Advanced Cell Technology Athersys California Stem Cell Cytori Therapeutics Mesoblast Opexa Therapeutics Caladrius Biosciences

Market Segment by Type, covers:

Stem Cell Transplant Autologous Transplant Allogenic Transplant Transplant Medicine Regenerative Medicine

Market Segment by Applications, can be divided into:

Therapeutics Service Companies Private And Government Research Institutes Academic Institutes Research Based Pharmaceutical Companies Public And Private Cord Blood Banks

Order Copy Umbilical Cord Blood (UCB) Stem Cell Market of this Report @https://www.orianresearch.com/checkout/753860

There are 15 Chapters to deeply display the global Umbilical Cord Blood (UCB) Stem Cell market.Chapter 1: Describe Umbilical Cord Blood (UCB) Stem Cell Introduction, product scope, market overview, market opportunities, market risk, and market driving force.Chapter 2: Analyze the top manufacturers of Umbilical Cord Blood (UCB) Stem Cell Tablet, with sales, revenue, and price of Umbilical Cord Blood (UCB) Stem Cell Tablet, in 2015 and 2017.Chapter 3: Display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2017.Chapter 4: Show the global market by regions, with sales, revenue and market share of Umbilical Cord Blood (UCB) Stem Cell Tablet, for each region, from 2011 to 2017.Chapter 5, 6, 7, 8 and 9: Analyze and talked about the key regions, with sales, revenue and market share by key countries in these regions.Chapter 10 and 11: Show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2017.Chapter 12: In Chapter Eleven Umbilical Cord Blood (UCB) Stem Cell market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022.Chapter 13, 14 and 15: Describe Umbilical Cord Blood (UCB) Stem Cell sales channel, distributors, traders, dealers, appendix and data source.

Customization Service of the Report:Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessitiesAbout Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (415) 830-3727 | UK: +44 020 8144-71-27Email: info@orianresearch.comWebsite:www.orianresearch.com/

Continued here:
Umbilical Cord Blood (UCB) Stem Cell Market 2019 Industry Analysis focusing on Companies Analysis-Advanced Cell Technology, Athersys, California Stem...

Rat Model Market revenue to hit $1.8 billion by 2025: Global Market Insights, Inc. – GlobeNewswire

Selbyville, Delaware, Dec. 05, 2019 (GLOBE NEWSWIRE) --

Global Rat Model Market value is set to surpass USD 1.8 billion by 2025, according to a new research report by Global Market Insights, Inc. Growing usage of rat models in the development of novel vaccines and increase in the adoption of rat models for conducting various research studies on diseases such as autoimmune diseases, cancer, cardiovascular diseases are some of the factors that will majorly drive the rat model industry growth over the projected timeframe.

Rat model is defined as the use of animals to study the development and advancement of diseases since there are various similarities between humans and rats. The upsurge of rat models in biological research studies coupled with functional resemblances of rats to human body are few factors boosting the market growth in the upcoming years. Growing number of animal testing procedures for ensuring drug safety and regular use of rat model in animal testing owing to its genetic similarities with humans are also few factors that are offering significant traction to the market growth. Rats are one of the animals that are widely used in the medical research since they are the primary model for mechanistic studies of human reproduction. Hence, all these factors are expected to boost the adoption of rat models across the globe and is further projected to boost the market growth in the upcoming years.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/4165

On the basis of rat type, the rat model market is segmented as inbred, outbred, knockout, hybrid and others. The inbred rat model business held the maximum share of over 25.0% in 2018. Upsurge of rat models in autoimmune disorder research is rapidly increasing as rat models can mimic autoimmune diseases that affect humans and these models offer a large scale of tissue samples than mice models. These factors further assist researchers to understand the mechanism of diseases that will further play a significant role in propelling the global market growth in the near future.

Some major findings of the rat model market statistics report include:

Based on technology, the rat model market is segmented into CRISPR, microinjection, embryonic stem cell, nuclear transfer and others. The CRISPR technology market accounted for 31.5% market share in 2018. Rapid growth of CRISPR technology is owing to certain advantages such as ease of use, cost-effectiveness, time saving, and greater efficiency required to alter target genes compared to other gene targeting technologies. Hence, the above-mentioned advantages enhance the demand and adoption of CRISPR technology in rat model industry, thereby boosting the business growth.

Browse key industry insights spread across 450 pages with 376 market data tables & 11 figures & charts from the report, Rat Model Market Size By Rat Type (Inbred, Outbred, Knockout, Hybrid), By Technology (CRISPR, Microinjection, Embryonic Stem Cell, Nuclear Transfer), By Application (Research & Development, {Infectious Disease, Immunological Disease, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases}, Production And Quality Control, Academics), By Use (Human, Veterinary), By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-Government}, Academic And Research Institutes, Contract Research Organizations) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Switzerland, Netherlands, Czech Republic, Poland, Belgium, Finland, Hungary, Denmark, Ireland, Sweden, China, Japan, Australia, South Korea, New Zealand, Taiwan, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE, Israel), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 2025 in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/rat-model-market

On the basis of application, the market is segment into research & development, production and quality control, academics and others. The research and development segment held the largest revenue share at around 72.2% in the year 2018. The demand of rat models for research and development is in order to check the cognitive function that rats and humans share. Since rats are able to remember wider variety of tasks, it in turn helps the researchers to perform several studies on rats about memory and learning. Hence, such factors are responsible for boosting the rat model market growth for research and development.

On the basis of use, rat model is segmented into human and veterinary. The use of animal model for humans held the highest market share of over 80% in the year 2018. Rise in testing procedures on rats for understanding of diseases such as cardiovascular diseases and diabetes among others that can harm humans is propelling the market growth. Furthermore, increase in the number of rat models for understanding the biological behavior of diseases such as cardiovascular diseases, autoimmune diseases and cancer are few factors that are expected to impel the segmental growth.

On the basis of end-use, rat model industry is segmented into companies, organizations, academic & research institutes and contract research organizations. Companies held the highest market share of over 61.2% in the year 2018. Growing number of research & development activities in the biotech and pharma industry that demands for animal testing for confirming the efficacy and safety of drugs along with the development of novel vaccines are propelling the segmental growth.

The U.S. rat model market is estimated to expand at more than 8.0% CAGR over the projected period. As per the American Burn Association, around 486,000 people were reported at emergency departments for burn/fire injuries. Therefore, various research institutes in the country are conducting physiological tests that rats and humans share in order to mimic the human skin structure. Hence, owing to this, the demand for rat model will significantly escalate in the near future.

Key players are executing several growth strategies such as acquisitions and mergers in order to increase their geographic presence and their product portfolio. For instance, in April 2019, Charles River Laboratories completed the acquisition of Citoxlab. The acquisition would lead to important expansion of the treatment option, thereby resulting in better quality of life. It will further bolster the companys global position by expanding its scientific product portfolio, that will in turn enhance their client partner relations across the drug discovery and development continuum.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/4165

Browse Related Reports:

Animal Model Market Analysis Report 2025: On the basis of animal type, the animal model market is segmented as mice, rats, fish, birds, cattle, pigs, amphibians, rabbits, guinea pigs, dogs, cats, sheep, hamsters, monkeys, and others. The mice market held the maximum share of over 51.7% and was valued at around USD 7 billion in the year 2018. The upsurge of mice models in cancer research is burgeoning owing to low-cost factors and widespread availability. Some of the prominent industry players include Charles River, Envigo, genOway, Horizon Discovery Group Plc, Harbour BioMed, Taconic Biosciences, Inc., Janvier Labs, The Jackson Laboratory and TRANS GENIC Inc, Ltd.

https://www.gminsights.com/industry-analysis/animal-model-market

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Read the original post:
Rat Model Market revenue to hit $1.8 billion by 2025: Global Market Insights, Inc. - GlobeNewswire

Dosage analysis of the 7q11.23 Williams region identifies BAZ1B as a major human gene patterning the modern human face and underlying…

INTRODUCTION

Anatomically modern humans (AMHs) exhibit a suite of craniofacial and prosocial characteristics that are reminiscent of traits distinguishing domesticated species from their wild counterparts (13). This has led to the formulation of a self-domestication hypothesis according to which modern humans (3) went through a domestication process in the course of their evolution. Recent evidence, along with the well-warranted distinction between domestication and selective breeding (4), is also extending this notion to other species that might have undergone a self-domestication phase, such as cats, dogs, and bonobos (3). Thus, as self-domestication represents a special case of domestication, the most parsimonious hypothesis must posit the same core mechanisms to underlie both. For this reason, the self-domestication hypothesis also entails the prediction that key aspects of modern humans anatomy and cognition can be illuminated by studies of the so-called domestication syndrome, the core set of domestication-related traits that was recently proposed to result from mild neural crest (NC) deficits (5). However, both the neurocristopathic basis of domestication and its extension to the evolution of AMHs remain to be tested experimentally.

Williams-Beuren syndrome [WBS; OMIM (Online Mendelian Inheritance in Man) 194050] and Williams-Beuren region duplication syndrome (7dupASD; OMIM 609757), caused respectively by the hemideletion or hemiduplication of 28 genes at the 7q11.23 region [WBS critical region (WBSCR)], represent a paradigmatic pair of neurodevelopmental conditions whose NC-related craniofacial dysmorphisms and cognitive/behavioral traits (6, 7) bear directly on domestication-related traits relevant for AMHs (facial reduction and retraction, pronounced friendliness, and reduced reactive aggression) (fig. S1A). Structural variants in WBS genes, for example in the case of GTF2I and its paralogs, have been shown to underlie stereotypical hypersociability in domestic dogs and foxes (8, 9).

Among the WBSCR genes, we focus here on the chromatin regulator BAZ1B (also known as Williams syndrome transcription factor, WSTF), on the basis of the following lines of evidence that implicate it in domestication-relevant craniofacial features: (i) its established role in NC maintenance and migration in Xenopus laevis and the craniofacial defects observed in knockout mice (10, 11); (ii) the observation that its expression is affected by domestication-related events in canids (12); (iii) the first formulation of the neurocristopathic hypothesis of domestication, which included BAZ1B among the genes influencing NC development (5); (iv) the most comprehensive studies focusing on regions of the modern human genome associated with selective sweep signals compared to Neanderthals/Denisovans (hereafter archaics) (13, 14), one of which specifically included BAZ1B within the detected portions of the WBSCR; and (v) the thus far most detailed study systematically exploring high-frequency (HF) (>90%) changes in modern humans for which archaic humans carry the ancestral state, which found BAZ1B enriched for mutations in modern humans (most of which fall in the regulatory regions of the gene) (15).

Our previous work had established the largest cohort of 7q11.23 patient-derived induced pluripotent stem cell (iPSC) lines and revealed major disease-relevant transcriptional dysregulation that was already apparent at the pluripotent state and became further exacerbated upon differentiation (16). Here, we first harness this resource to dissect the impact of BAZ1B dosage on the NC of patients with WBS and 7dupASD, both in terms of function (i.e., NC migration and induction) and of transcriptional and chromatin dysregulation, thereby defining the BAZ1B dosagedependent circuits controlling the NC. Next, we apply these experimentally determined BAZ1B-dependent circuits underlying craniofacial morphogenesis to interrogate the evidence from paleogenomic analyses, which were thus far only of a correlative nature. We find major convergence between the BAZ1B control and the genes harboring regulatory changes in the modern human lineage. Together, the definition of the role of BAZ1B dosage in craniofacial neurocristopathy and its application to domestication-relevant paleogenomics demonstrate a major contribution of BAZ1B to the modern human face and offer experimental validation for the prediction at the heart of NC-based accounts of (self-) domestication: that the modern human face acquired its shape as an instance of mild neurocristopathy.

To dissect the role of BAZ1B in the craniofacial dysmorphisms that characterize WBS and 7dupASD, we started from our previous characterization of WBS patient and 7dupASD patientspecific iPSC lines and differentiated derivatives (16) and selected a cohort of 11 NC stem cell (NCSC) lines (four from patients with WBS, three from patients with 7dupASD, and four from control individuals), which also represent the largest cohort of patient-specific NCSCs described so far. Given the centrality of the cranial NC for the development of the face, we first validated the cranial identity of our NCSC cohort by transcriptomic profiling through a manually curated gene expression signature (fig. S2A), confirming their suitability for the study of craniofacial dysregulations. We then knocked down BAZ1B via RNA interference in all lines across the three genetic conditions, including also NCSCs derived from a particularly informative patient with atypical WBS (hereafter atWBS) bearing a partial deletion of the region that spares BAZ1B and six additional genes (Fig. 1A) (17). To establish a high-resolution gradient of BAZ1B dosages, we selected two distinct short hairpin RNA (shRNA) against BAZ1B (i.e., sh1 and sh2) along with a scrambled shRNA sequence (hereafter scr) as negative control, for a total of 32 NCSC lines. Knockdown (KD) efficiency was evaluated at the RNA level by quantitative polymerase chain reaction (qPCR) (Fig. 1B and fig. S1C), confirming the attainment of the desired gradient with an overall reduction of about 40% for sh1 and 70% for sh2, as well as reduction at the protein level, as detected by Western blot (fig. S1E).

(A) Schematic representation of the KD strategy on our iPSC-derived NCSC cohort. (B) BAZ1B mRNA levels in all the interfered lines (scr, sh1, and sh2) as measured by qPCR. Data represent aggregates of samples with the same number of BAZ1B copies (7dup, CTL + atWBS, and WBS). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is used as a normalizer. (C) Eight- and 16-hour time points from the wound-healing assay analyses performed on a 7dupASD and a WBS NCSC line upon BAZ1B KD. Cells from the same line infected with the scr sh were used as references for the migration (n = 2). (D) Days 7, 10, and 12 of NC differentiation from embryoid bodies (EBs) of an scr-interfered iPSC line and its respective BAZ1B KD (n = 3). (E) mRNA levels of NC markers at day 12 of differentiation in three individual experimental replicates [bright-field images are reported in (D)]. An iPSC line is included as a negative control. Students t test was used (ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0. 0001).

NCSCs need to migrate to reach specific target regions in the developing embryo and give rise to distinct cell types and tissues, including craniofacial structures that are major areas of change in human evolution. Since BAZ1B KD was shown to affect the migration of the NC in X. laevis and to promote cancer cell invasion in different lung cancer cell lines (10, 18), we hypothesized that the BAZ1B dosage imbalances entailed in the 7q11.23 syndromes could result in a defective regulation of NCSC migration and might underlie the NC-related alterations typical of patients with WBS and 7dupASD. To test this, we compared the migration properties of patient-specific BAZ1B KD NCSC lines (sh2) to their respective control NCSC line (scr) by the well-established wound-healing assay. The 7dupASD NCSC KD lines took longer to fill the wound when compared to the respective control lines (scr), as indicated by images taken at 8 and 16 hours after a gap was created on the plate surface (Fig. 1C and fig. S1F). We instead observed an opposite behavior for the WBS BAZ1B KD lines, which were faster than the respective scr lines in closing the gap (Fig. 1C and fig. S1F). In contrast to the previous observations from X. laevis (10), we also observed a minor delay in NC induction as a consequence of BAZ1B KD (Fig. 1D and fig. S1D), by means of a differentiation protocol based on NC delamination from adherent embryoid bodies (EBs), which recapitulates the initial steps of NC generation (19). In particular, starting from 2 to 3 days after attachment of EBs, we observed a lower number of outgrowing cells in the KD line (Fig. 1D, days 7 and 10), coupled with an evidently higher cell mortality. Cells were eventually able to acquire the typical NC morphology, although lower differentiation efficiency was evident, as shown by images taken at day 12. In addition, the delay in NC formation was associated with a down-regulation of well-established critical regulators of NC migration and maintenance, including NR2F1, NR2F2, TFAP2A, and SOX9 (Fig. 1E). These results show that BAZ1B regulates the developing NC starting from its earliest migratory stages and that the symmetrically opposite 7q11.23 dosages alterations prime NCSCs to symmetrically opposite deficits upon BAZ1B interference. In turn, the central role of the NC in the development of facial morphology allows relating such findings to the symmetrically opposite craniofacial dysmorphisms of the two 7q11.23 syndromes.

Having defined the functional impact of BAZ1B dosage on NC function, we predicted that a main molecular readout of its dosage imbalances would be at the level of transcriptional regulation, given its critical role as transcriptional regulator in different cell and animal models (2022). To test this hypothesis and gain mechanistic insights into the specific BAZ1B dosagedependent downstream circuits, we subjected 32 interfered NCSC lines to high-coverage RNA sequencing (RNA-seq) analysis. As shown in fig. S2A, a manually curated signature from an extensive literature review (2328) validated the cranial identity of our NCSC lines, while clustering by Pearson correlation excluded the presence of any genotype- or hairpin-specific expression change. Confirming our previous observations in the two largest cohorts of iPSC lines (29), a principal component analysis (PCA) corroborated the significant impact of individual genetic backgrounds on transcriptional variability, with most KD lines clustering with their respective control scr line. This was consistent with the narrow range of experimentally interfered BAZ1B dosages and pointed to a selective BAZ1B dosagedependent transcriptional vulnerability (fig. S2B).

To dissect it, we thus resorted to a combination of classical pairwise comparative analysis, contrasting shBAZ1B-interfered NCSC lines (sh1 + sh2) with their respective controls (scr), with a complementary regression analysis using BAZ1B expression levels as independent variables, subtracting the contribution of individual genetic backgrounds. This design increases robustness and sensitivity in the identification of genes that, across multiple genetic backgrounds and target gene dosages, might have a different baseline (scr) across individuals while still being robustly dysregulated upon BAZ1B interference.

The two analyses identified a total of 448 genes with false discovery rate (FDR) < 0.1 (1192 with P < 0.01 and FDR < 0.25) whose transcriptional levels followed BAZ1B dosage, in either a direct (202; 539 with P < 0.01 and FDR < 0.25) or an inverse (246; 653 with P < 0.01 and FDR < 0.25) fashion. In addition, genes identified in the regression analysis included around 90% of the differentially expressed genes (DEGs) (27 of 29, FDR < 0.1) found in the comparative analysis (Fig. 2A). Consistent with the differential efficiency of the two short hairpins, we found a globally stronger transcriptional impact for the group of samples targeted by sh2 (fig. S2C) and a milder but nevertheless clearly distinguishable effect of sh1, resulting in particularly informative gradient of dosages over the scr control lines.

(A) Overlap between genes directly or inversely following BAZ1B levels identified in the pairwise comparative analysis (scr versus shBAZ1B) and in the regression analysis on BAZ1B-level sensitive genes on iPSC-derived NCSCs (FDR < 0.1). (B) Volcano plot reporting DEGs identified in the RNA-seq analysis on iPSC-derived NCSCs [fold change (FC) > 1.25; FDR < 0.1]. (C) Top most specific enrichments for GO biological processes among the DEGs in the RNA-seq analysis on iPSC-derived NCSCs. (D) Heat map representing DEGs that are dysregulated in genetic disorders involving mental retardation (Mental), intellectual disability (Intellectual), and/or facial dysmorphisms (Face) according to OMIM database classification. cnv, copy number variant. (E) Putative regulators of genes that follow BAZ1B levels identified by a master regulator analysis. Regulators were divided in four different groups based on their main functions.

Particularly noteworthy among the genes that we found correlated with BAZ1B levels were (i) crucial regulators of cranial NC, further highlighting a convergent BAZ1B dosagedependent dysregulation of the foundational CUL3-centered regulatory axis orchestrating NC-mediated craniofacial morphogenesis (30), and (ii) genes associated with variation of human facial shape or causative of dysmorphic facial features and mild intellectual disability when mutated (Fig. 2B and table S1).

Gene Ontology (GO) analysis performed on genes directly following BAZ1B levels suggested specific enrichments in biological processes such as histone phosphorylation, chromosome localization, RNA processing, and splicing. Genes inversely following BAZ1B levels were instead enriched in categories particularly relevant for NC and NC-derivative functions, such as cell migration and cardiovascular and skeletal development (Fig. 2C). By querying the OMIM database, we found that several DEGs were associated with genetic disorders whose phenotypes include mental retardation, intellectual disability, and/or facial dysmorphisms (Fig. 2D), underscoring the pertinence of BAZ1B-dependent dysregulation across both the neurocristopathic and cognitive axes.

Last, a master regulator analysis identified candidate regulators of BAZ1B DEGs, including factors involved in enhancer marking [CEBPB, p300, RBBP5, HDAC2 (histone deacetylase 2), KDM1A, and TCF12], promoter activation [TBP (TATA boxbinding protein), TAF1 (TBP-associated factor 1), and POL2 (polymerase 2)], and chromatin remodeling (CTCF, RAD21, and YY1) (Fig. 2E and fig. S2D), several of which are themselves causative genes of intellectual disability syndromes with neurocristopathic involvement, as in the case of our recently identified Gabrielede Vries syndrome caused by YY1 haploinsufficiency (31, 32). Chromatin remodeling was indeed the most prominently enriched group within the overall domain of transcriptional regulation. Two master regulators are particularly noteworthy, as they are themselves regulated by BAZ1B dosage. The first is EGR1 (FDR < 0.1), which is itself among the genes inversely correlated with BAZ1B levels, which is implicated in cranial development (in animal models) (33, 34) and whose promoter has been recently shown to feature a bivalent state in human embryonic cranial NC (23, 35). The second is MXI1, identified as master regulator of genes directly following BAZ1B levels (FDR < 0.001), which is itself found among the genes inversely correlated with BAZ1B and is itself a regulator of BAZ1B, pointing to a cross-talk between the two (fig. S2C). Notably, two differentially expressed targets of MXI1, TGFB2 and NFIB, are also involved in intellectual disability and craniofacial defects (30, 36, 37).

The transcriptional readout and functional impact of BAZ1B dosage (at the level of NC induction and migration) established its role as a master controller of the NC. We thus predicted, on the basis of its molecular function, that BAZ1B would directly bind to key NC target genes and that for some of these, the binding would be dosage sensitive. These genes would be, in turn, the most likely direct targets to mediate the dosage-dependent transcriptional and functional phenotypes described above. To test this prediction, we set out to both identify BAZ1B direct targets and characterize their promoter and enhancer states, so as to mechanistically link their transcriptional dysregulation with BAZ1B dosagedependent chromatin binding. Given the absence of chromatin immunoprecipitation (ChIP)grade BAZ1B antibodies, to carry out our ChIP coupled with sequencing (ChIP-seq) on scr and KD lines, we first designed a tagging strategy to establish, by CRISPR-Cas9 editing, a series of in-frame 3xFLAG endogenously tagged BAZ1B alleles in representative iPSCs of the four genotypes (Fig. 3A and fig. S3, A and B). These were then differentiated to NCSCs (fig. S3C) and subjected to ChIP-seq with anti-FLAG antibody, enabling a faithful characterization of BAZ1B genome-wide occupancy across dosages (one tagged allele in WBS, two tagged alleles in atWBS and CTL, and two tagged alleles in the context of 1.5-fold dosages in 7dupASD).

(A) Schematic representation of the strategy for CRISPR-Cas9mediated tagging of endogenous BAZ1B. Briefly, iPSCs from the four genotypes were electroporated with the donor plasmid and the Cas9/single-guide RNA ribonucleoprotein complex; clones were selected via hygromycin and PCR, differentiated to NCSCs, and then subjected to ChIP-seq. (B) PCA showing the distribution of the four BAZ1B-tagged NCSC lines according to their chromatin profiles. (C) Overlap between genes expressed in our NCSC lines (purple) and genes bound by BAZ1B at their enhancer (red) or promoter (blue) regions. (D) Top most specific enrichments for GO biological processes among the genes that are bound by BAZ1B and expressed in our NCSC cohort. (E) Most represented BAZ1B DNA binding motifs identified by HOMER show high similarity to neural and NCSC-specific transcription factors motifs. (F) BAZ1B differentially bound regions according to its copy number (FDR < 0.1; n = 2). (G) Overlap between genes that are differentially expressed have their enhancers differentially marked concordantly (H3K27ac, H3K4me1, and H3K27me3) and are bound by BAZ1B at enhancers.

PCA shows a clear separation of the samples by BAZ1B copy number, with CTL and atWBS samples clustering more closely and WBS and 7dupASD samples clustering at opposing positions (Fig. 3B). To call NC-specific enhancer regions and promoter-enhancer associations, we exploited for chromatin annotation the unprecedented resolution afforded by the patients cohort with its underlying variability and proceeded to (i) select chromosomal regions featuring H3K4me1 and H3K27ac in at least two individuals; (ii) exclude regions marked with H3K4me3 in at least two individuals;(iii) eliminate regions bearing a transcription start site (TSS); and (iv) associate each putative enhancer to the closest TSS, identifying a total of 30,8470 putative enhancer regions. Notably, BAZ1B binds 75% of its targets at their enhancer regions (6747 genes), with the remaining 2297 targets bound at promoters (Fig. 3C). In addition, 40% of genes expressed in NC are bound by BAZ1B, either exclusively at enhancers (27.4%) or exclusively at promoters (3.5%) or at both regions (9%). This highlights its pervasiveness within the NC epigenome (Fig. 3C) and is also reflected in the key functional enrichments observed for the BAZ1B direct targets that are also expressed and that include axon guidance, tube development, dendrite development, outflow tract morphogenesis, odontogenesis, wound healing, and endochondral bone morphogenesis (Fig. 3D). Many of the phenomena captured by these GO categories (e.g., odontogenesis and endochondral bone morphogenesis) are linked to recent changes in the bone structure of modern (versus archaic) humans, with Homo sapiens having characteristically smaller teeth than its extinct relatives.

Last and consistent with the enrichments in NC-defining categories uncovered above, the analysis of BAZ1B bound regions revealed major convergence with the binding motifs of critical NC regulators, including two motifs similar to those of TFAP2A and NEUROG2, and one equally associated to TAL1, TCF12, AP4, and ASCL1 (Fig. 3E and text S1A). Thus, BAZ1B binding regions are enriched for target sites of major regulators of NC and its neural derivatives (38, 39), among which TFAP2A stands out given its core role in neural border formation and NC induction and differentiation (40) through the binding and stabilization of NC-specific enhancers, in concert with NR2F1, NR2F2, and EP300 (41).

Last, we identified 81 regions that are quantitatively bound by BAZ1B depending on its copy number (FDR < 0.1) (Fig. 3F), 153 regions differentially bound concordantly in WBS and 7dupASD compared to control and atWBS samples (FDR < 0.1) (fig. S4A), and 176 and 25 regions differentially bound preferentially in WBS (fig. S4B) and 7dupASD (FDR < 0.1) (fig. S4C), respectively.

Given the prominence of its binding to distal regulatory regions, we then set out to define the BAZ1B dosagedependent impact on NCSC-specific enhancers by integrating H3K27ac, H3K4me1, H3K27me3, and H3K4me3 profiles. We thus performed a regression analysis on BAZ1B levels for the distribution of the three histone marks in the aforementioned regions and found H3K27ac to be the most affected, with 7254 genes differentially acetylated at their enhancers, followed by a differential distribution of the H3K4me1 (4048) and H3K27me3 (2136) marks (fig. S4D). This enabled the overlay of epigenomic and transcriptomic profiles, uncovering that among the 1192 DEGs identified in the regression RNA-seq analysis, 21.3% (257 of 1192) are associated to enhancers that are both bound by BAZ1B and differentially H3K27-acetylated in a manner concordant with BAZ1B levels (fig. S4E), with a stronger overlap for genes whose expression is inversely correlated with BAZ1B levels (160 versus 97). The same held for DEGs that have a concordant differential distribution of H3K4me1 mark at enhancers (123 versus 55), underscoring the consistency of the impact of BAZ1B dosage on distal regulation (fig. S4F). In contrast, a lower number of genes (36) showed a concordant differential distribution of the H3K27me3 mark and, at the same time, were bound by BAZ1B at enhancers (fig. S4G), indicating that BAZ1B preferentially affects active chromatin. From this integrative analysis, we could thus lastly identify a core set of 30 bona fide direct targets of BAZ1B, which are genes whose expression tightly follows BAZ1B levels and whose enhancers are bound by BAZ1B and clearly differentially modified (Fig. 3G, fig. S4H, and text S1B). Together, this first dosage-faithful analysis of BAZ1B occupancy in a diverse cohort of human NCSCs establishes its pervasive and mostly distal targeting of the NC-specific epigenome, with a preferential activator role on the critical transcriptional circuits that define NC fate and function.

Mild NC deficits have been put forth as a unifying explanatory framework for the defining features of the so-called domestication syndrome, with BAZ1B listed among the putative underlying genes because of its previously reported role in the NC of model organisms (5, 10, 11). The recent observation that its expression is affected by domestication-related mobile element insertion methylation in gray wolves (12) further supported its role in domestication, offering an intriguing parallel to the paleogenomic results that had detected BAZ1B within the regions of the modern genome reflective of selective sweeps and found it enriched for putatively regulatory mutations in AMHs (15).

Having defined the molecular circuits through which BAZ1B regulates NC, and since NC changes have been implicated in the domestication syndrome (5), since craniofacial differences correlate with self-domestication (1), and since 7q11.23 dosage-related craniofacial differences in humans relate to the H. sapiens versus Neanderthal comparison (fig. S1A), we set out to test the role of BAZ1B dosage in the differences between modern and archaic humans. For this, we carried out a systematic integrative analysis of the overlaps between our empirically defined BAZ1B dosagesensitive genes (blue Venn in Fig. 4B) and a combination of uniquely informative datasets highlighting differences between modern humans and archaics (Neanderthals/Denisovans) (represented in Fig. 4A by skulls illustrating the more gracile and juvenile profile in AMH relative to Neanderthals visible in the overall shape of the neurocranium, reduced prognathism, brow ridges, and nasal projections) (1, 1315). Specifically, as shown in Fig. 4B, these datasets include (i) genes associated with signals of positive selection in the modern branch compared to archaic lineages (purple Venn) (13, 14); (ii) genes harboring (nearly) fixed mutations in moderns versus archaics (pink Venn); and (iii) genes associated with signals of positive selection in the four paradigmatic domesticated species dog, cat, cattle, and horse (1) (orange Venn), to reveal statistically significant overlaps between them and genes associated with signals of positive selection in the modern branch compared to archaic lineages. In turn, the list of genes harboring (nearly) fixed mutations in moderns versus archaics contains three classes: (i) genes harboring high-frequency changes (15), (ii) genes harboring high-frequency missense mutations (red barplot), and (iii) genes enriched for high-frequency mutations in regulatory regions (green barplot) [data based on (15)] (Fig. 4C). As shown in the barplots, the obviously very limited number of high-quality coverage archaic genomes available results in a much higher number of nearly fixed changes identified in archaics (left/negative side of the plot) versus modern humans (right side) (Fig. 4C), setting a comparatively much higher threshold for the identification of nearly fixed modern changes.

(A) Archaic (Neanderthal) and modern skulls, illustrating the target domesticated phenotype that was captured by our analysis. Skull images were derived from work under a CC BY-SA 2.0 license (https://creativecommons.org/licenses/by-sa/2.0/deed.en) by hairymuseummatt. (B) Overlap between BAZ1B levelsensitive genes and datasets, which bring out differences between AMHs and archaics, as well as genes under positive selection in modern humans and domesticates. (C) Barplots showing the occurrence of high-frequency changes, missense mutations, and mutations in regulatory regions in genes from the AMH (nearly) fixed mutation dataset (pink Venn in B). (D) Heat map representing the amount of overlaps for each list selected from (B). Gene overlaps and detailed list descriptions are reported in table S2. (E) Rendering of a typical WBS face (left) against the background of a typical modern face (right). Red segments indicate areas of the lower face where the two faces most sharply depart (nose, philtrum, and lower front of the mandible). The lower midface region is most often associated with mutations in genes figuring prominently in our intersections, as discussed in the text and table S3.

These analyses are visualized in Fig. 4D (and detailed in tables S2 and S3) through a matrix that intersects all BAZ1B dosagedependent genes (partitioned in the two categories of directly and inversely correlated and ordered across the full range of biological significance and regulatory proximity, from simply DEGs to bona fide direct targets) with the evolutionary changes underlying domestication and self-domestication, yielding the following key insights (color coded for degree of overlap and marked for significance in hypergeometric tests). First, the most significant pattern was obtains at the intersection with the top 10% genes showing an excess of (nearly) fixed mutations in the regulatory regions of modern humans compared to archaics, across both directly and inversely BAZ1B leveldependent genes (table S2). This same category of nearly fixed modern regulatory changes is also the only one that returns a statistically significant overlap with the most stringent core of BAZ1B dosagedependent targets (i.e., DEGs whose enhancers are both directly bound by BAZ1B and differentially marked upon its decrease), demonstrating that BAZ1B directly controls, in an exquisitely dosage-dependent manner, this coherent and particularly relevant set of genes that underwent regulatory changes in human evolution. Second, the overall strongest overlaps map to the class of genes that are inversely correlated to BAZ1B levels, which we found to be strongly and specifically enriched for head morphogenesis and NC categories (Fig. 2C), thereby confirming craniofacial morphogenesis as the key domain of functionally relevant overlap between BAZ1B dosage and (self-) domestication changes relevant to the evolution of AMHs. Third, despite the spuriously inflated number of apparently fixed mutations in archaics (15), the overall extent of overlap between genes affected by BAZ1B dosage and our modern and archaic sets does not reveal significantly more hits for archaics. Globally, we found consistently more overlapping genes between the BAZ1B targets and the modern human data and even no statistically significant overlap for any list of the archaic-specific mutations when crossed against genes directly correlated to BAZ1B level. We find this noteworthy, given the evidence that the Neanderthal face also displays derived characteristics (42) that could be the result of modifications of genes that could overlap with those highlighted in this work. Last, the (lower) midface emerges as a particularly salient area of functionally relevant overlap (as illustrated in Fig. 4E and detailed in table S3), given the specific genes that our analysis unearthed: (i) COL11A1, one of the few craniofacial genes highlighted across domestication studies (dog, house sparrow, and pig breeds), which lies in a region of the human genome that resisted archaic introgression (13) and is associated with Marshall syndrome; (ii) XYLT1, one of the five genes (along with ACAN, SOX9, COL2A1, and NFIX) that affect lower and midfacial protrusion, are among the top differentially methylated genes compared to archaics and were also highlighted in a recent study on regulatory changes that shaped the modern human facial and vocal anatomy (tables S1 and S3) (43); and (iii) NFIB, which belongs to the same gene family as NFIX and shares some of its functions. In sum, the direct and dosage-sensitive control by BAZ1B of genes that underwent regulatory changes in human evolution and whose altered expression underlies neurocristopathic facial dysmorphisms is consistent with the hypothesis of mild neurocristopathy as the mechanistic core selected in the self-domestication of the modern human face.

As recently reconstructed (3), the idea of human self-domestication dates back, at least in terms of scientific record, to Johann Friedrich Blumenbach at the onset of the 19th century. Following on his seminal account of domestication systematized in Variations of Animals and Plants under Domestication (44), Charles Darwin also considered the analogy between modern humans and domesticated species in The Descent of Man (45), yet his emphasis on controlled breeding as a key aspect of domestication led him to frame domestication and self-domestication as distinct phenomena and thereby leave Blumenbachs intuition largely undeveloped (46). Since then, the possibility that the anatomical and cognitive-behavioral hallmarks of AMHs could result from an evolutionary process bearing such significant similarities to the domestication of animals as to share the same underlying cause has been refined into the full-fledged self-domestication hypothesis (1, 2). As recently argued (1, 3), convergent lines of evidence also indicate that self-domestication is temporally aligned with the emergence of AMH, although the process may have acquired further momentum with the gradual expansion of our species (1, 3). However, despite spurring considerable interest, the self-domestication hypothesis has thus far failed to marshal conclusive evidence largely because of two factors: (i) the lack of a coherent explanation, even at a theoretical level, of what developmental and genetic mechanisms could underlie domestication in general and (ii) the absence of suitable experimental systems in which those mechanisms could be specifically tested in the case of human self-domestication. The first problem was tackled by the recent proposition of mild NC deficits as a central and unifying functional layer underlying domestication (5). This constituted a major conceptual advance, particularly because it generated the testable hypothesis of an altered NC gene expression program in domesticated species relative to their wild-type ancestors. For humans, given the obvious lack of gene expression data from archaic hominins, we reasoned that this hypothesis could be verified by examining the genetic changes between archaic and modern humans in light of the gene regulatory networks directly inferred from human neurocristopathies. We thus set out to test whether specific human neurodevelopmental disorders, carefully selected on the basis of both craniofacial and cognitive-behavioral traits relevant to domestication, could illuminate the regulatory circuits shaping the modern human face and hence be harnessed for an empirical validation of the self-domestication hypothesis. Specifically, we reasoned that WBS and 7dupASD, through their uniquely informative set of symmetrically opposite phenotypes at the level of face morphology (fig. S1A) and sociality, constituted a paradigmatic test case to probe the heuristic potential of neurodevelopmental disease modeling for the experimental understanding of human evolution. The following key insights confirm the validity of this approach.

First, we identified the 7q11.23 region BAZ1B gene as a master regulator of the modern human face on the basis of a molecular and functional dissection in the thus far largest cohort of WBS patient and 7dupASD patientspecific NCSCs and across an exhaustive range of BAZ1B dosages. Notably, our cohort also included NCSCs from a patient with rare WBS featuring a much milder WBS gestalt and harboring an atypical, BAZ1B-sparing deletion that served as a particularly informative control, as confirmed by the clustering of atypical NCSC lines with controls when probed for BAZ1B occupancy. In particular, exploiting the fine-grained resolution of BAZ1B dosages recapitulated in our cohort, we could couple classical pairwise comparisons with a more sophisticated regression analysis on BAZ1B levels, thereby revealing major BAZ1B dosagedependent transcriptional alterations pivoting around clusters of pathways that are crucial for NC development and maintenance, as well as for its downstream skeletal and cardiac outputs.

Second, we repurposed the versatility of CRISPR-Cas9 to generate an allelic series of endogenously tagged BAZ1B across 7q11.23 dosages (including the BAZ1B-sparing atypical patient as uniquely relevant control) to define its dosage-dependent genome-wide occupancy. Taking advantage of previous extensive work on the NCSC chromatin landscape (41, 4749), we were able to define a pivotal role for BAZ1B in NCSC enhancer regulation, consistent with its preferential binding of distal regulatory regions, and to partition its dosage-dependent regulation into bona fide direct and indirect targets. The overall balance between the numbers of genes up- or down-regulated upon BAZ1B KDtogether with the greater overlap, sheer size, and significance of enrichments in chromatin remodeling categories over other domains of transcription regulationfurther corroborates the inclusion of BAZ1B among the factors acting upstream of enhancer and promoter modulations to enable or reinforce rather than specify their net outcome. Last, this molecular readout was translated to the functional level with the definition of an impairment in both NCSC migration and outgrowth from EBs upon decrease in BAZ1B, providing the first validation of BAZ1B involvement in key functions of the developing human NC.

Third, our investigation provides the first experimental evidence for the neurocristopathic hypothesis that had been put forth to explain the domestication syndrome and had pointed to BAZ1B as one of the candidates underlying this syndrome (5). Among the key NC hubs affected by BAZ1B dosage, we uncovered three additional critical genesEDN3, MAGOH, and ZEB2that had also been predicted in the same model because they are associated with behavioral changes found in domesticates, thereby defining a regulatory hierarchy for this coherent set of genes underlying domestication.

Last, the empirical determination of BAZ1B dosagesensitive genes in NC models from AMHs with accentuated domestication-relevant traits allowed us to expose, in a functionally relevant manner, the genetic differences between modern versus archaic. This brought to the fore the significant convergence between BAZ1B-dependent circuits and genes harboring regulatory changes in the human lineage, reinforcing the notion that regulatory regions contain some of the most significant changes relevant for the modern lineage. This is also reinforced by the recent identification of AMH-specific hypermethylation in the regulatory region of BAZ1B itself (43).

Last, it is noteworthy that genes implicated in NC development also play significant roles in the establishment of brain circuits that are critical for cognitive processes like language or theory of mind prominently affected in 7q11.23 syndromes. Among the genes downstream of BAZ1B that we uncovered in this study, FOXP2, ROBO1, and ROBO2 have long been implicated in brain wiring processes critical for vocal learning in several species (50, 51), including humans, and will warrant further mechanistic dissection in light of the distinctive linguistic profile of WBS individuals. In conclusion, our findings establish the heuristic power of neurodevelopmental disease modeling for the study of human evolution.

Ethics approvals were reported in the study that established the original iPSC cohort (16) and also apply to the additional samples included in this study (7dupASD3 and CTL4R).

WBS1, WBS2, WBS3, WBS4, 7dupASD1, atWBS1, and CTL2 fibroblasts were reprogrammed using the mRNA Reprogramming Kit (Stemgent), while the 7dupASD2 and CTL1R lines were reprogrammed with the microRNA Booster Kit (Stemgent). The CTL3 line was reprogrammed by transfection with the STEMCCA polycistronic lentiviral vector followed by Cre-mediated excision of the integrated polycistron. 7dupASD3 and CTL4R fibroblasts were reprogrammed using the Simplicon RNA Reprogramming Kit (Millipore).

Before differentiation, iPSC lines were cultured on Matrigel hESC-qualified Matrix (BD Biosciences)coated plates, diluted 1:40 in Dulbeccos minimum essential medium/F-12, and grown in mTeSR 1 medium (STEMCELL Technologies). They were passaged upon treatment with Accutase (Sigma-Aldrich) and then plated in mTeSR 1 medium supplemented with 5 M Y-27632 (Sigma-Aldrich).

Differentiation into NCSCs was performed as previously described (52), with the exception of NCSCs used in the experiment reported in Fig. 1 (D and E) (19).

NCSCs were detached using Accutase and counted, and 1 106 cells per experimental condition were fixed in 4% paraformaldehyde and then blocked in 10% bovine serum albumin. Cells were incubated for 1 hour with primary antibodies conjugated to fluorophores (HNK1fluorescein isothiocyanate and nerve growth factor receptorAlex Fluor 647; BD Biosciences). Analyses were performed on a FACSCalibur instrument (BD Biosciences), and data were analyzed with FCS express software (Tree Star). Fluorescence-activated cell sorting characterization for 7dupASD3 and CTL4R lines is reported in fig. S1B; for all the other lines, see (16).

BAZ1B KD was performed using validated pLKO.1 TRC vector TRCN0000013338 (referred to as sh1) and TRCN0000013341 (referred to as sh2). A pLKO.1 TRC vector containing a scrambled short hairpin sequence was used as a negative control.

Second generation lentiviral vectors were produced through calcium phosphate transfection of human embryonic kidney 293T cells and ultracentrifugation (2 hours, 20C, 20,000 rpm).

NCSCs (3 to 4 105) were infected upon splitting and then selected by adding puromycin (1 g/ml) to the medium.

RNA was extracted using the RNeasy Micro Plus Kit (QIAGEN) according to the manufacturers instructions. Retrotranscribed cDNA was obtained from 0.5 to 1 g of total RNA using the SuperScript VILO retrotranscription kit (Thermo Fisher Scientific).

Real-time qPCR was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems) using SYBR Green Master Mix (Applied Biosystems) as the detecting reagent. A total cDNA amount corresponding to 15 ng of starting RNA was used for each reaction. Each sample was analyzed in triplicate and normalized to GAPDH. Relative mRNA quantity was calculated by the comparative cycle threshold (Ct) method using the formula 2Ct [BAZ1B, CCTCGCAGTAAGAAAGCAAAC (forward) and ACTCATCCAGCTCCTTTTGAC (reverse); GAPDH, GCACCGTCAAGGCTGAGAAC (forward) and AGGGATCTCGCTCCTGGAA (reverse); NR2F1, AGAAGCTCAAGGCGCTACAC (forward) and GGGTACTGGCTCCTCACGTA (reverse); NR2F2, GCAAGTGGAGAAGCTCAAGG (forward) and GCTTTCCACATGGGCTACAT (reverse); TFAP2A, GCCTCTCGCTCCTCAGCTCC (forward) and CGTTGGCAGCTTTACGTCTCCC (reverse); and SOX9, AGTACCCGCACTTGCACAAC (forward) and GTAATCCGGGTGGTCCTTCT (reverse)].

Library preparation for RNA-seq was performed according to the TruSeq Total RNA sample preparation protocol (Illumina), starting from 250 ng to 1 g of total RNA. cDNA library quality was assessed in an Agilent 2100 Bioanalyzer using the High Sensitivity DNA Kit. Libraries were sequenced with the Illumina HiSeq machine at a read length of 50base pair (bp) paired end and a coverage of 35 million of reads per sample.

NCSCs were lysed in radioimmunoprecipitation assay buffer [10 mM tris (pH 8.0), 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, and 1 mM EDTA] supplemented with protease inhibitor cocktail (Sigma-Aldrich) and 0.5 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich) for 1 hour at 4C.

Protein extracts (30 to 50 g per sample) were supplemented with NuPAGE LDS sample buffer (Thermo Fisher Scientific) and 50 mM dithiothreitol (Thermo Fisher Scientific) and denatured at 95C for 3 min. Then, extracts were run on a precast NuPAGE 4 to 12% bis-tris Gel (Thermo Fisher Scientific) in NuPAGE MOPS SDS Running Buffer (Thermo Fisher Scientific) and transferred to a 0.45-m nitrocellulose membrane (GE Healthcare) for 1 hour at 100 V in a buffer containing 20% absolute ethanol and 10% 0.25 M tris base and 1.9 M glycine. The membranes were blocked in TBST [50 mM tris (pH 7.5), 150 mM NaCl, and 0.1% Tween 20] and 5% milk for 1 hour, incubated with primary antibodies overnight at 4C and with secondary antibodies for 1 hour at room temperature. Primary [BAZ1B (Abcam) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Millipore)] and secondary antibodies were diluted in TBST and 5% milk. Blots were detected with the ECL Prime Western Blotting Detection Reagents (Sigma-Aldrich) and scanned using the ChemiDoc system (Bio-Rad).

Cells (5 104 to 7 104) were plated in each of the two Matrigel-coated wells of silicone culture-inserts (Ibidi) attached to six-well culture plates. After 24 hours, the insert was removed, medium was changed to remove dead cells, and time lapse was performed for 24 hours at the rate of one image every 10 min at 10 magnification; each condition was analyzed in duplicate. Images were acquired with the BX61 upright microscope equipped with a motorized stage from Olympus or the Nikon Eclipse Ti inverted microscope equipped with a motorized stage from Nikon and analyzed with ImageJ.

iPSCs were pretreated with 10 M rho kinase inhibitor for 4 hours, and then 2 106 cells were electroporated using the Neon system with the Cas9/single-guide RNA ribonucleoprotein complex and the donor plasmid (synthesized by GeneArt). The donor plasmid contained three FLAG tags followed by a self-cleaving peptide (P2A) and a hygromycin resistance (HygroR). The 3xFLAG-P2A-HygroR cassette was flanked by BAZ1B-specific homology arms (5 HA and 3 HA) to promote homologous recombination and then subcloned into a bacterial backbone (Fig. 3A).

After 48 hours, iPSC medium was supplemented with hygromycin B (50 g/l), and selection medium was maintained for 15 days. Fifteen to 20 clones per iPSC line were then subjected to PCR to (i) evaluate the presence of the cassette and the insertion in the correct genomic locus and (ii) distinguish heterozygously tagged from homozygously tagged clones (fig. S3A). We could isolate a clone with a homozygous integration from the CTL, the atWBS, and the typical WBS but not from the 7dupASD line. In the 7dupASD clone, the FLAG tag was present in two of three copies, as shown by a digital PCR analysis (fig. S3B).

DNA (60 ng) was amplified in a reaction volume containing the following reagents: QuantStudio 3D Digital PCR Master Mix v2 (Thermo Fisher Scientific), Custom TaqMan Copy Number Assays SM 20 FAM labeled (Thermo Fisher Scientific), and TaqMan Copy Number Reference Assay 20 (Thermo Fisher Scientific) VIC labeled (Thermo Fisher Scientific). The mix was loaded on a chip using the QuantStudio 3D Digital PCR Chip Loader. The chips were then loaded on the ProFlex PCR System (Thermo Fisher Scientific), and data were analyzed using the QuantStudio 3D AnalysisSuite Cloud Software. The entire process was performed by the qPCR Service at Cogentech, Milano [Custom (FLAG) TaqMan Copy Number Assays: forward primer, TGGACAGTCCAGAGGACGAA; reverse primer, CACCCTTGTCGTCATCGTCTT; and probe, FAMACAGAAGAAGGACTACAAAGACG and TaqMan Copy Number Reference Assay: TERT (VIC) (catalog number 4403316)].

Approximately 2 105 cells were used (~100 g of chromatin) for histone mark IP, and 1 mg of chromatin was used for BAZ1B-FLAG IP. Cells were fixed with phosphate-buffered saline, containing 1% formaldehyde (Sigma-Aldrich), for 10 min to cross-link proteins and DNA, when the reaction was then stopped by adding 125 mM glycine for 5 min. Cells were lysed with SDS buffer containing 100 mM NaCl, 50 mM tris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), and 10% SDS, at which point chromatin pellets were resuspended in IP buffer containing 1 volume of SDS buffer and 0.5 volume of Triton dilution buffer [100 mM tris-HCl (pH 8.5), 5 mM EDTA (pH 8.0), and 5% Triton X-100]. Chromatin was then sonicated using the S220 Focused-ultrasonicator (Covaris) to generate <300 bp DNA fragments (for histone mark IPs) or the Branson Digital Sonifier to generate 500 to 800 bp DNA fragments (for BAZ1B-FLAG IP).

Sonicated chromatin was incubated overnight at 4C with primary antibodies [H3K27ac (Abcam), H3K4me1 (Abcam), H3K4me3 (Abcam), H3K27me3 (Cell Signaling Technology), and FLAG (Sigma-Aldrich)] and then for 3 hours with Dynabeads Protein G (Thermo Fisher Scientific). Beads were washed three times with low-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM tris-HCl (pH 8.0), and 150 mM NaCl] and once with high-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM tris-HCl (pH 8.0), and 500 mM NaCl]. Immunocomplexes were eluted in decross-linking buffer (1% SDS and 100 mM NaHCO3) at 65C for 2 hours. DNA was purified using QIAquick PCR columns (QIAGEN) and quantified with a Qubit dsDNA HS assay kit (Thermo Fisher Scientific). DNA libraries were prepared by the sequencing facility at European Institute of Oncology according to the protocol described by Blecher-Gonen and colleagues (53), and DNA was sequenced on the Illumina HiSeq 2000 platform. For the FLAG ChIP, samples were run in duplicate.

RNA-seq data were quantified using Salmon 0.91 to calculate read counts and transcripts per million in a transcript- and gene-wise fashion, using the quasi-mapping offline algorithm (54) on the GRCh38 (National Center for Biotechnology Information) database. edgeR was used for differential gene expression analysis (DEA), using generalized linear regression methods, to identify pattern of differential expression following two different schemes:

1) A factorial analysis based on the definition of one group of scrambled and one group of KD samples to identify genes dysregulated similarly across short hairpins characterized by different efficiencies.

2) A numerical analysis in which log-normalized [Trimmed Mean of M-values (TMM)] BAZ1B levels, as quantified by RNA-seq, was used as independent variable.

All analyses were performed dropping individual variations (~individual+KD or ~individual+BAZ1B) to account for the genetic background of each individual. In particular, this design is expected to permit the identification of genes, which change expression level upon KD even in situations in which genotype-specific makeups would lead BAZ1B-dependent genes to have unique expression levels in scramble lines. In the factorial analysis, DEGs were identified and characterized by filtering for fold change (FC) > 1.25 and FDR < 0.05 unless explicitly indicated.

To our knowledge, performing a regression analysis at a gene-specific level has never been performed. We were able to do this because of the availability of a large set of samples (11 individuals) and because of the two short hairpins robustly respectively reducing BAZ1B expression levels, respectively by ~40 and ~70% in all individuals lines. To validate the quality of our numerical differential expression analysis, we took advantage of HipSci data (55, 56) and iPSCpoweR tools (29). We took 50 of 105 possible combinations of 13 random individual RNA-seq data from the healthy HipSci cohort, representing both sexes and having at least two technical replicates per individual. Unfortunately, HipSci does not contain at least 13 individuals with three clones per individual. Thus, we performed four alternative DEAs with edgeR (table S4) on the 50 different random combinations of 13 individuals identified (200 DEAs in total, on 22 samples, two clones per individual), using the same model matrix used for the regression analysis (~individual+BAZ1B) and using BAZ1B levels of scramble and sh2 lines. All analyses identified very low number of spurious DEGs (fig. S2E). Thus, we used the Edg2 pipeline (table S4) because it does not discard genes with higher variability (Edg2 and Edg4 versus Edg1 and Edg3), and it is based on a better suited algorithm (Edg2 versus Edg4). With our model matrix, filtering by P < 0.01 (and FDR < 0.25), using Edg2 on a random HipSci data, we obtained an average of 93.32 DEGs (on average) with a median equal to 43 (table S5). GO enrichments were performed using topGO R package version 2.28.0.

Master regulatory analysis was performed via hypergeometric test by measuring gene set enrichments in lists of transcription factor targets provided by the TFBS tools database (57). Both GO and transcription factor enrichment analyses were performed considering background genes expressed in at least two samples in our NCSC cohort.

ChIP-seq experiments were analyzed both qualitatively and quantitatively. Reads were trimmed with the FASTX-Toolkit (-Q33 -t 20 -l 22), aligned with Bowtie 1.0 (-v 2 -m 1) on the Human hg38 reference genome, and peaks were called using MACS 2.1.1. H3K4me1, H3K27ac, H3K4me3, and H3K27me3 peaks were called with --broad using default parameters and q < 0.05.

Qualitative analysis, including intersection and comparison of bed files, was performed using BedTools version 2.23.

To define enhancer regions, we intersected those marked by H3K4me1 and H3K27ac in at least two samples, discarded regions with H3K4me3 in at least two samples, and discarded regions overlapping with TSS. Motif enrichment was performed by using HOMER v4.10.

Quantification of reads per region was performed with DeepTools 3.0.2. Differential mark deposition was conducted by means of edgeR 3.24.1 inside R 3.3.3. To define mark deposition following BAZ1B levels, we used the same design as for RNA-seq data (~individual+BAZ1B).

To identify BAZ1B bound regions and to avoid losing identification of lowly covered regions, we resorted to (i) aggregation of all sample aligned reads and (ii) peak calling with MACS2 using extsize 800 and q < 0.25. BAZ1B binding coverage was calculated with DeepTools, with the same parameters used for histone marks, on the identified peak regions. Differentially bound regions were identified with edgeR.

The archaic/modern lists were generated from the material presented in (15). We used high-coverage genotypes for three archaic individuals: one Denisovan (58), one Neanderthal from the Denisova cave in Altai mountains (59), and another Neanderthal from Vindija cave, Croatia (60). The data are publicly available at http://cdna.eva.mpg.de/neandertal/Vindija/VCF/, with the human genome version hg19 as reference. High-frequency (HF) differences were defined as positions where more than 90% of present-day humans carry a derived allele, while at least the Denisovan and one Neanderthal carry the ancestral allele. High-frequency changes in archaics were defined as occurring at less than 1% in present-day humans, while at least two archaic individuals carry the derived allele. The HF lists used here were examined as presented in (15), with the exception of the HF lists in regulatory regions, which were extracted from the same dataset but not presented as such in the original paper.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/5/12/eaaw7908/DC1

Fig. S1. BAZ1B KD validation in iPSC-derived NCSCs and evaluation of its impact on NCSC migration.

Fig. S2. BAZ1B KD affects the transcriptome of iPSC-derived NCSCs.

Fig. S3. Generation of BAZ1B-FLAG iPSC lines and differentiation to NCSCs.

Fig. S4. BAZ1B KD induces a significant chromatin remodeling at distal regions.

Text S1A. Detailed description of HOMER motif enrichments performed on BAZ1B ChIP-seq data.

Text S1B. List of key direct targets of BAZ1B involved in neural- and NC-related development and relevant associated literature.

Table S1. Genes relevant for NC and NC-derived features whose expression follows BAZ1B levels.

Table S2A. Significant genes in human evolution.

Table S2B. Regulatory excess in archaic humans, overlap with BAZ1B targets.

Table S2C. Mutation excess in archaic humans, overlap with BAZ1B targets.

Table S2D. Regulatory changes (exclusive) in archaic humans, overlap with BAZ1B targets.

Table S2E. Missense mutations in archaic humans, overlap with BAZ1B targets.

Table S2F. Mutation excess in archaic humans corrected for length, overlap with BAZ1B targets.

Table S2G. Regulatory excess in modern humans, overlap with BAZ1B targets.

Table S2H. Mutation excess in modern humans, overlap with BAZ1B targets.

Table S2I. Regulatory changes (exclusive) in modern humans, overlap with BAZ1B targets.

Table S2J. Missense mutations in modern humans, overlap with BAZ1B targets.

Table S2K. Mutation excess in modern humans corrected for length, overlap with BAZ1B targets.

Table S2L. Genes under positive selection in domesticated animals, overlap with BAZ1B targets.

Table S2M. Genes under positive selection from Peyrgne et al. (13) in modern humans, overlap with BAZ1B targets.

Table S2N. Genes under positive selection from Racimo (14) in modern humans, overlap with BAZ1B targets.

Table S3. Crucial genes identified in the overlap between BAZ1B datasets and archaic versus modern human datasets reported in this study.

Table S4. Alternative differential expression analysis functions tested with iPSCpower to assess the efficacy of our design matrix (~individual+BAZ1B). R code provided.

Table S5. Number of genes differentially expressed following BAZ1B data in our numerical analysis compared to an analysis conducted on randomized HipSci data, using Edg2 function (see table S4).

References (6189)

Read more from the original source:
Dosage analysis of the 7q11.23 Williams region identifies BAZ1B as a major human gene patterning the modern human face and underlying...

Stem Cell Banking Market expected to Witness a Sustainable Growth over 2028 – VaporBlash

Global Stem Cell Banking Market: Overview

The demand within the global stem cell banking market is growing on account of advancements in the field of regenerative medicine. The medical fraternity has become extremely focused towards the development of artificial tissues that can infuse with the human body. Furthermore, medical analysis and testing has gathered momentum across biological laboratories and research institutes. Henceforth, it is integral to develop stem cell samples and repositories that hold relevance in modern-day research. The need for regenerative medicine emerges from the growing incidence of internal tissue rupture. Certain types of tissues do not recover for several years, and may even be damaged permanently. Therefore, the need for stem cell banking is expected to grow at a significant pace.

Download Brochure of This Market Report at https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6111

In a custom report, TMR Research digs into the factors that have aided the growth of the global stem cell banking market. The global stem cell banking market can be segmented on the basis of bank size, application, and region. The commendable developments that have incepted across the US healthcare industry has given a thrust to the growth of the North America stem cell banking market.

Global Stem Cell Banking Market: Notable Developments

The need for improved regenerative medication and anatomy has played an integral role in driving fresh developments within the stem cell banking market.

Gallant has emerged as a notable market entity that has remained as the torchbearer of innovation within the global stem cell banking market. The company has recently launched stem cell banking for dogs, and has attracted the attention of the masses. As people become increasingly concerned about their pets, the new move by Gallant shall help the company in earning the trust of the consumers. Moreover, it can move several notches higher on the innovation index.

Cells4Life has also remained at the forefront of developments within the global stem cell banking market. After suffering backlash for its error in cord blood stem cell promotion, the company is expected to use effective public relation strategies to regain its value in the market.

Global Stem Cell Banking Market: Growth Drivers

Development of improved facilities for storage of stem cells has played an integral role in driving market demand. Furthermore, the unprecedented demand for improved analysis of regenerative medications has also created new opportunities within the global stem cell banking market. Medical research has attracted investments from global investors and stakeholders. The tremendous level of resilience shown by biological researchers to develop stem cell samples has aided market growth. Henceforth, the total volume of revenues within the global stem cell banking market is slated to multiply.

Commercialization of stem cell banks has emerged as matter of concern for the healthcare industry. However, this trend has also helped in easy storage and procurement of cells stored during the yester years of children. Presence of sound procedures to register at stem cell banks, and the safety offered by these entities, has generated fresh demand within the global market. New regional territories are opening to the idea of stem cell banking. Several factors are responsible for the growth of this trend. Primarily, improvements in stem cell banking can have favourable impact on the growth of the healthcare industry. Moreover, the opportunities for revenue generation associated with the development of functional stem cell banks has aided regional market growth.

The global stem cell banking market is segmented on the basis of:

Source

Request For TOC On this Market Report at https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6111

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

View original post here:
Stem Cell Banking Market expected to Witness a Sustainable Growth over 2028 - VaporBlash

Adult Stem Cells- Global Healthcare Research and Survey with Key Participants Celyad, Cytori Therapeutics Inc. – Planet InfoWar

Market Research Explorepublished an explanatory study on theGlobal Adult Stem Cells Marketto illuminate the structure of the market, the performance of rival firms, and segment that approaches Adult Stem Cells buyers in a wiser way. The report precisely evaluates the market size, share, revenue, profitability, and development rate over the last five years and provides reliable forecasts to prompt clients to operate their Adult Stem Cells business accordingly. An intense study of the historical, present, and forthcoming status of the market made the report more eloquent and prudent.

Increased spending and utilization of the Adult Stem Cells across the world are boosting the market to exhibit a growing CAGR during the forecast period. Similarly, rising disposable incomes, product awareness, technological advancements, product innovations, and market stability also generate profitability in the global Adult Stem Cells market. The market has been performing with a growing development rate over the last decade. It is expected to grow even better in the near future.

Request Global Adult Stem Cells Market Sample Report

Adult Stem Cells manufacturers are also executing superior activities in the market to gain a considerable revenue share. They are performing several tasks such as product research, innovation, developments, and technology adoptions to deliver more effective products/services in the industry. The report further highlights their business strategies including mergers, acquisitions, partnerships, as well as product launches, and brand promotions that help clients to gain extensive comprehension of market positions, strengths, and weaknesses of their rivals.

Leading companies operating in the Global Adult Stem Cells Market are:

Cellular Dynamics International, Celyad, Cytori Therapeutics Inc., Intellicell Biosciences Inc., International Stem Cell Corp., Gamida Cell Ltd., Biotime Inc., Juventas Therapeutics Inc., Caladrius Biosciences Inc., Brainstorm Cell Therapeutics Inc., Mesoblast Ltd., Beike Biotechnology Co. Ltd., Cellerix Sa

Purchase extensive global Adult Stem Cells research study

The report also sheds light on companies financial assessment that comprises precise evaluation of gross margin, Adult Stem Cells sales volume, revenue, growth rate, production cost, pricing structure, financial ratios, cost structure, expenses, and other vital factors. Additionally, the report explores crucial elements such as company manufacturing base, Adult Stem Cells production volume, capacity, value chain, product specifications, raw material sourcing strategies, concentration rate, import-export activities, distribution network, serving segments, organizational structure, and global presence.

Adult Stem Cells types, applications, regions, and technologies are leading segments of the global Adult Stem Cells industry. The report enfolds detailed delineation of these segments based on their revenue, development prospects, production, demand, and market size. The referred segmentation analysis also covers extensive regional analysis considering major regions such as North America, Europe, Middle East & Africa, South America, Asia, and significant countries from the rest of the world.

Get detailed explanation with TOC:https://www.marketresearchexplore.com/report/global-adult-stem-cells-industry-market-research-report/173055#toc

Moreover, the report highlights current and forthcoming market opportunities and challenges and prompts clients to convert them into lucrative business gains. Potential market threats, risks, obstacles, and uncertainties were also discovered in the report in order to help market players in lowering possible losses. The global Adult Stem Cells industry environment is also illuminated in the report alongside a profound evaluation of provincial market regulations, policies, trade frameworks, international trade disputes as well as social, political, financial, and atmospheric concerns that may harm Adult Stem Cells market profitability.

For any further questions, kindly connect with our industry experts atsales@marketresearchexplore.com.

Read this article:
Adult Stem Cells- Global Healthcare Research and Survey with Key Participants Celyad, Cytori Therapeutics Inc. - Planet InfoWar

Stem Cell Media Market 2019 Global Industry Insights, Innovations, Key Players Analysis, Growth Strategies and Forecast Analysis 2019 & 2026|…

This new research report that entirely centers Global Stem Cell Media Market 2019 is an exhaustive analysis of driving forces, risks, challenges, threats, and business opportunities, involved in the Stem Cell Media market. It offers conclusive specks of the market such as major leading players, market size over the forecast period of eight years, segmentation analysis, market share, current market trends, movements and major geographical regions involved. The report includes a comprehensive market study and competitors landscape with the addition of a SWOT study of the leading vendors.

This report analysis also studies the product and business strategy of some of the key vendors in the market. Considering the segmentation in the Stem Cell Media market, key vendors in the market are highlighting mergers and collaborations and advancing their supply chains.

Get Sample PDF Brochure (including full TOC, Tables, and Figures) of Stem Cell Media Market @ https://researchindustry.us/report/stem-cell-media-market-ric/697128/request-sample

THANKSGIVINGWe are offering Upto 40% Discount on the full report purchase! For transactions only till 5th December 2019.

Stem Cell Media Market Impressive Report Offerings:

Some of the Major Stem Cell Media Market Players Are:

TakaraPromoCellGE HealthcareMiltenyi BiotecCorningCellGenixLonzaThermo FisherSTEMCELL TechnologiesMerck MilliporeAnd Others

The global Stem Cell Media market report covers scope and product overview to describe the key terms and offers detailed information about market dynamics to the readers.

This is followed by the segmental analysis and regional outlook. The report also comprises of the facts and key values of the global Stem Cell Media market in terms of sales and volume, revenue and growth rate.

One of the significant factors in the global Stem Cell Media market report is competitive analysis. The report covers all the key factors such as product innovation, market strategies of the key players, market share, latest research and development, revenue generation, and market expert views.

For Best Discount on purchasing this report,(Price 2000 USD for a single-user license) Visit: https://www.researchindustry.us/checkout?report=697128&type=single

Stem Cell Media market regional Analysis

The global Stem Cell Media market is fragmented across the globe which not only includes the market of North America but covers the other regions such as Europe, the Asia Pacific, South America, and the Middle East.

North American countries, especially the U.S. and Canada represent noteworthy growth in this market. Similarly, Western European regions are also ahead in influencing the global markets.

Here are the questions we answer

Customize report and inquiry before the purchasing this report @ https://researchindustry.us/report/stem-cell-media-market-ric/697128/request-customization

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-844-601-6060

Email sales@researchindustry.us

See original here:
Stem Cell Media Market 2019 Global Industry Insights, Innovations, Key Players Analysis, Growth Strategies and Forecast Analysis 2019 & 2026|...

Stem Cell Source Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2024 – VaporBlash

As per the Researchunt market industry research Global Stem Cell Source market, global industry analysis, trend, size, share, growth in the database. This industrial research report presents all the valuable information related to the particular product for the Stem Cell Source market with highly enlightening format.

Global Stem Cell Source market gives you and large scale platform with full of golden opportunities to the particular industry, producers, firms, association industries and sellers that are continuously working on their business growth at a world level.

Order a copy of sample report @researchunt.com/report/global-stem-cell-source-market-research-report-2019-2025/#Free-Sample-Report

The Report gives an idea about market rate, size at the global level. The experts use the various methodology and analytical technique such as SWOT analysis to guess market growth, Global Stem Cell Source market report also focuses on different rules and policies introduced by the administration, Global Stem Cell Source market report present the market regarding information like the technology used, consumer application part, etc.

As per the analysis, huge information present in the Global Stem Cell Source market report helps the readers to enhance their decision making capability regarding the particular business at a significant price.

The method of data representation used in the Global Stem Cell Source market report is quite exciting thats added flowchart, graphs, statistics, etc.

Read Detailed Index of full Research Study at @ https://researchunt.com/report/global-stem-cell-source-market-research-report-2019-2025/

The key manufacturing in the Stem Cell Source:-

Market size split by type:-

Market size split by application:-

Market size split by regions:-

Abstract

Research goal:

To split the breakdown data by type, organization, and application

To analyze the challenging developments like agreements, new product launches.

To research the Global Stem Cell Source status and future forecast in the US, china involving value, sale, and growth rate.

Global Stem Cell Source market value and volume data for each segment.

Global Stem Cell Source market report mentions key financial information, recent development, SWOT analysis by the major market players.

Here Below questions us answers

What are the important trends and dynamics?

Where will most development take place in the long term?

Which regulation thats will impact the industry

What does the competitive landscape look like?

What are the future opportunities?

Reasons to Purchase the report:

Improve the decision-making process.

Learn about the driving factors, affecting the market report.

Progress in the market during the forecast period

Compare and evaluate different options affecting the market.

Deliver and modify business growth plans by using substantial growth offerings developed.

Research report analysis:

Organization reputation and outlook for major application

By product type growth factor and application

Manufactures in the global market and competitive companies

Check here for the [emailprotected] https://researchunt.com/report/global-stem-cell-source-market-research-report-2019-2025/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Read more from the original source:
Stem Cell Source Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2024 - VaporBlash

Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression via th | OTT – Dove Medical Press

Yaoyao Tong,1,2 Kun Tong,1,2 Qinghong Zhu,1 Yuqin Wu,3 Yi Yang,4 Jicai Zhang,1 Pei Hu,1,5 Shirong Yan2

1Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, Peoples Republic of China; 2Hubei Key Laboratory of Wudang Local Chinese Medicine Research, School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, Hubei, Peoples Republic of China; 3Department of Central Operating Room, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, Peoples Republic of China; 4Reproductive Medicine Centre, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, Peoples Republic of China; 5Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, Hubei, Peoples Republic of China

Correspondence: Shirong YanHubei Key Laboratory of Wudang Local Chinese Medicine Research, School of Pharmaceutical Sciences, Hubei University of Medicine, No. 30, South Renmin Road, Maojian District, Shiyan City, Hubei Province, Peoples Republic of ChinaEmail graceyan@163.comPei HuDepartment of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, No. 32, South Renmin Road, Maojian District, Shiyan City, Hubei Province, Peoples Republic of ChinaEmail hupei2018@taihehospital.com

Purpose: To investigate the role of glypican-3 (GPC3) in cobalt chloride (CoCl2)-induced cell apoptosis in hepatocellular carcinoma.Methods: HepG2 cells were treated with CoCl2 in the absence or presence of GPC3 plasmid transfection. Cell viability and apoptosis were assessed by MTT assay and flow cytometry, respectively. The expression of GPC3, hypoxia-inducible factor 1 (HIF-1), c-myc, sp1, poly-ADP-ribose polymerase (PARP) and caspase-3 was determined by real-time PCR, Western blotting, and immunofluorescence after the cells were treated with different concentrations of CoCl2 or siRNA targeting HIF-1.Results: CoCl2 significantly inhibited the proliferation of HepG2 cells and induced apoptosis. Additionally, the expression of GPC3 mRNA and protein was decreased, and overexpression of GPC3 attenuated the tumour inhibiting effects. Further studies showed that CoCl2 increased the expression of HIF-1 while reducing the expression of sp1 and c-myc; knockdown of HIF-1 elevated the expression of GPC3, sp1, and c-myc.Conclusion: CoCl2 inhibited the growth of HepG2 cells through downregulation of GPC3 expression via the HIF-1/c-myc axis.

Keywords: cobalt chloride, c-myc, glypican-3, hepatocellular carcinoma, hypoxia-inducible factor 1

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original post:
Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression via th | OTT - Dove Medical Press

Interview: Shaping the future – The Actuary

Futurist Ray Hammond talks to Stephen Hyamsabout revolutions in healthcare, the future of work and cryptocurrencies

05 DECEMBER 2019 | STEPHEN HYAMS

Ray Hammond has a long record of accurate foresight about the future, such as identifying the coming importance of the internet shortly after its launch.

How did he become a futurist?

It happened by accident, he says. After finishing with journalism, I wanted to become a writer. During a small book tour in San Diego, I met the well-respected futurist Alvin Toffler. We kept in touch and he encouraged me to broaden out beyond technology, which was then my focus, to understand the way that todays trends may shape reality in 10 to 20 years time.

The future of health

Hammond is excited by the current revolutions in healthcare, of which he expects digital health to havethe earliest impact. Within 10 to 15 years, perhaps30% of hospital inpatients will be at home in bed but monitored so thoroughly that its almost as if they were in the hospital, he says. A team of mobile nurses will take care of their physical needs. Its also going to have a profound impact on the way drugs are developed, because drug companies can use the data that flows back from digital devices to learn how were responding. Eventually, it will be as if every patient is taking part in a real-time clinical experiment.

DNA-based and stem cell medicine will also play a significant role during the next five to 10 years. For privacy reasons, it will take a while for people to accept having their DNA stored., says Hammond. For many people, DNA stands for do not ask. Once the benefits of DNA analysis are understood fully, the word will spread and, with full consideration for privacy and data protection, DNA-based medicine will be an enormously powerful tool. He cites the detection of genetic abnormalities in the earliest stages of embryonic development during pregnancy as an example.

Its early days for stem cell medicine, but Hammond predicts that it will become very important within 10 years. It seems to have so many applications, a bit like penicillin, and promises to deal with lots of diseases that are currently intractable. Using stem cells from ones own body avoids the risk of rejection. Im certain that in 10 years time we will be taking organs off the shelf, or theyll be grown to order for us.

Hammond believes two other healthcare revolutions will have longer-term implications. The first is nanoscale medicine, which he believes will have a huge impact, but not for another 20 years. Manipulating molecules at the nanoscale level will enable the production of drugs designed to produce specific proteins that are tailored for certain illnesses. Nanoparticles are currently being developed for the targeted delivery of drugs, while there is some research involving nanoparticles that seeks to develop a vaccine for influenza. Hammond believes the other healthcare revolution will be in gene editing to enable removal of damaging pieces of DNA from a patients tissue but care is needed to avoid it affecting the germline, for fear of unintended consequences.

Healthcare outlook

What will be the collective impact of these developments? During the next 20 to 30 years they will transform healthcare, and I think it is likely we will see a return to higher rates of mortality improvements in the UK, following the period of lower rates seen during the past few years.

Hammond is excited by two recent pieces of research into anti-ageing, one of which removes senescent cells from the body. These cells are widely believed to contribute to ageing. The other work involves therapyto reprogram genes to reverse the ageing process.

In human trials, there have been some startling achievements in a single year, 70% to 80% of the patients had their biological clock reversed by two and a half years, he says. The results were so stunning that the researchers have easily been able to raise the money to carry out much wider trials. Until a year ago, I was highly sceptical about rejuvenation and life extension, but not any longer. By 2030 or 2040 I think we could see some patients extending their lives as healthy centenarians. Within the next 20-30 years, Hammond also thinks that most types of cancer will be controllable, as opposed to being cured.

How can we meet the cost of healthcare for an ageing population? During the next 10 years it will be a problem, but there are indications that things will improve significantly, mostly thanks to digital technology, says Hammond. The key is 5G networks, which will be super-fast and reliable, with instant, real-time responses and no bandwidth problems. This will facilitate distributed care, in which many patients are monitored from their homes, thereby taking the pressure off hospital space. The healthcare revolutions will mean fewer people in hospital, and for less time.

The collection and analysis of healthcare data is developing fast, and it must remain secure for people to remain comfortable in providing it. Could insurers seek to use the data for underwriting purposes? There are currently legal barriers to the discriminatory use by insurers of DNA information, while they are also no longer allowed to ask the catch-all question of whether there is any other information that would be relevant.

Digital monitoring devices will not be for everyone, while those who do use them will need clear instructions explaining that they are not fully accurate and no substitute for proper medical advice.

Robotics will have developed to the point where most of the non-medical tasks in a hospital are handled by machines, Hammond says. For example, a robot nurse in triage could perform standard tests before passing the patient to a doctor, if necessary. Remote robotic surgery will also become very efficient oneeye specialist in London might be treating people anywhere in the UK, or around the world. Another interesting development is the growing use of virtual reality as an alternative to conventional anaesthetic.

Technology and work

Will robotics and automation put jobs at risk? During the next 15 years, there will be a lot of disruption in the workplace, says Hammond. Peoples roles will change, and retraining will be needed, but there will still be a lot of demand for human employment. After that period, Im not so sure; by the mid-2030s I think robots will be so ubiquitous, powerful and capable that a lot of human endeavour will not be needed. Robots will be increasing productivity to such an extent that society will have enough money to give to people who are not employed.

Such a fundamental change brings challenges, though. For many people, work is part of their identity, and when theyre denied it an important part of their life disappears, Hammond says. I dont have the answerto that, but Im worried.

Part of the solution is to recognise and pay for carers in the family, and Hammond predicts there will still be plenty of demand here. Robots will empathise and form attachments, but when real help or comfort is needed,I think well want a human for the foreseeable future.

I ask about the impact of artificial intelligence (AI)on replacing human work. Today AI is, at best, as intelligent as a rodent. I think it will be at least 30 years before AI is a threat to humanity in terms of its decision-making capabilities.

Cryptocurrencies and cash

Hammond expects blockchain technology, invented for the cryptocurrency Bitcoin, to have a huge and wide-ranging impact. Blockchain will be everywhere for example, managing patients in hospitals, or the assets and policies of an insurance company. The biggest drawback is its high energy demand, but there have been recent breakthroughs in that respect.

Cryptocurrencies do not need an issuing bank or government to authenticate them, as they are self-authenticating, so this poses a threat to the conventional banking industry and national sovereignty over finance, he continues. I dont see it happening on a big scale within 10 years, but in the longer term, if political will allows, there is no doubt that cryptocurrencies will replace fiat currencies.

Does this signal the end of cash? In my 1983 book Computers and Your Child I predicted there would be no cash in society by the year 2000, Hammond says.I was looking at the technology, and in that respect my prediction could have been correct, but I was forgetting human psychology. People like to feel they hold cash.I think cash will still be around in 10-15 years, but very much reduced.

I conclude by asking Hammond what his biggest concern for the future is. Climate change, with the extreme weather events that are going to become more frequent and severe and continue for at least the next30-40 years.

What excites him the most? The continuing improvement in human health. I love the idea of looking to a future where most serious illness is eradicated, with far less human suffering.

See the original post:
Interview: Shaping the future - The Actuary